Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG<sub>4</sub> response.

EBioMedicine · 2019 · PMC6921329 · PMID 31786130

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

6 (B)) showed a trend of increase towards September of the first treatment year, but there was no significant difference in IL-4 or IL-5 secretion between placebo and BM32 treated groups at any of the time points analysed.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG&lt;sub&gt;4&lt;/sub&gt; response.

The sentences

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG<sub>4</sub> response.